Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

ASM8: Phase IIa data

May 14, 2012 7:00 AM UTC

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article